KURA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KURA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Kura Oncology is: No Data: Cannot be evaluated.
For the Biotechnology subindustry, Kura Oncology's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kura Oncology's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Kura Oncology's Risk Assessment falls into.
Kura Oncology (NAS:KURA) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Kura Oncology's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian T. Powl | officer: Chief Commercial Officer | C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131 |
Thomas Malley | director | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Thomas James Doyle | officer: SVP, Finance & Accounting | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Kirsten Flowers | officer: Chief Commercial Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Kathleen Ford | officer: Chief Operating Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Stephen Dale | officer: Chief Medical Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Teresa Brophy Bair | officer: Chief Legal Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Helen Louise Collins | director | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Carol Schafer | director | 42 WHITE STREET, FOURTH FLOOR, NEW YORK NY 10013 |
Troy Edward Wilson | director, officer: President and CEO | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Marc Grasso | officer: CFO, CBO | C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121 |
Bridget A Martell | officer: Acting Chief Medical Officer | C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
James Basta | officer: Chief Legal Officer | C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121 |
Diane L. Parks | director | 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540 |
Antonio Gualberto | officer: Chief Medical Officer | 245 FIRST STREET, SUITE 1820, CAMBRIDGE MA 02142 |
From GuruFocus
By Marketwired • 09-19-2023
By Marketwired • 10-04-2023
By Marketwired • 10-17-2023
By sperokesalga sperokesalga • 06-14-2023
By sperokesalga sperokesalga • 05-23-2023
By sperokesalga sperokesalga • 05-30-2023
By sperokesalga sperokesalga • 04-18-2023
By sperokesalga sperokesalga • 05-03-2023
By Marketwired • 08-03-2023
By Stock market mentor Stock market mentor • 02-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.